BTIG Research Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price

Abbott Laboratories (NYSE:ABT) had its price target cut by stock analysts at BTIG Research from $140.00 to $131.00 in a research note issued on Tuesday,Benzinga reports. The brokerage presently has a “buy” rating on the healthcare product maker’s stock. BTIG Research’s price target would indicate a potential upside of 27.92% from the company’s previous close.

Other research analysts have also recently issued reports about the company. Barclays lowered their price objective on Abbott Laboratories from $169.00 to $142.00 and set an “overweight” rating on the stock in a research report on Monday, February 2nd. Sanford C. Bernstein reduced their target price on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a report on Friday, January 23rd. Piper Sandler lowered their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a report on Friday, January 23rd. Leerink Partners dropped their price target on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research report on Friday, January 30th. Finally, Citigroup decreased their price objective on shares of Abbott Laboratories from $140.00 to $136.00 and set a “buy” rating on the stock in a research report on Wednesday, March 11th. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $135.68.

Abbott Laboratories Trading Down 0.3%

Shares of Abbott Laboratories stock opened at $102.41 on Tuesday. Abbott Laboratories has a 1-year low of $100.88 and a 1-year high of $139.06. The company’s fifty day simple moving average is $109.68 and its 200-day simple moving average is $121.44. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.18. The stock has a market capitalization of $178.36 billion, a PE ratio of 27.53, a P/E/G ratio of 1.64 and a beta of 0.79.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, hitting the consensus estimate of $1.50. The firm had revenue of $11.46 billion during the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a return on equity of 17.73% and a net margin of 14.72%.Abbott Laboratories’s revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the business posted $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. As a group, equities analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current year.

Insider Activity

In other Abbott Laboratories news, EVP Mary K. Moreland sold 613 shares of the firm’s stock in a transaction that occurred on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the completion of the transaction, the executive vice president owned 104,291 shares in the company, valued at $12,053,953.78. This trade represents a 0.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, SVP Eric Shroff sold 709 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $115.58, for a total transaction of $81,946.22. Following the sale, the senior vice president directly owned 39,164 shares in the company, valued at approximately $4,526,575.12. The trade was a 1.78% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 3,055 shares of company stock valued at $353,097. 0.46% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Abbott Laboratories

A number of institutional investors and hedge funds have recently modified their holdings of ABT. J. Derek Lewis & Associates Inc. purchased a new position in Abbott Laboratories during the fourth quarter worth $1,992,000. Purpose Unlimited Inc. purchased a new stake in shares of Abbott Laboratories in the fourth quarter valued at $25,000. Stance Capital LLC lifted its holdings in shares of Abbott Laboratories by 12.8% in the 4th quarter. Stance Capital LLC now owns 11,339 shares of the healthcare product maker’s stock worth $1,421,000 after acquiring an additional 1,291 shares during the last quarter. Cornerstone Planning LLC purchased a new position in shares of Abbott Laboratories during the 4th quarter worth about $2,858,000. Finally, Rockefeller Capital Management L.P. grew its holdings in Abbott Laboratories by 27.5% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,377,659 shares of the healthcare product maker’s stock valued at $172,607,000 after purchasing an additional 297,268 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Abbott joined a $575M funding round for wearable maker Whoop as a strategic investor, positioning ABT to participate in consumer health/wearables and personalized‑health data opportunities that could broaden diagnostics and subscription revenue pathways. Abbott joins $575M funding round for wearable maker Whoop
• Positive Sentiment: Abbott integrated its Precision Oncology testing portfolio into Flatiron’s OncoEMR, improving workflow for oncology providers and potentially raising test ordering and revenue capture in oncology diagnostics. Abbott integrates Precision Oncology portfolio into Flatiron’s OncoEMR
• Positive Sentiment: Analyst optimism: Seeking Alpha noted a rating upgrade into Q1 earnings, suggesting some analysts see improving fundamentals and an attractive entry point after recent weakness. Upgrades can help limit downside and attract value buyers. Abbott: A Brighter Investment Case Heading Into Q1 Earnings (Rating Upgrade)
• Neutral Sentiment: Analyst commentaries and comparisons (GEHC vs ABT and sector roundups) are driving attention but not a clear consensus; some authors highlight valuation appeal while noting macro and currency risks. GEHC or ABT: Which Is the Better Value Stock Right Now?
• Neutral Sentiment: Investor guides and sector lists name Abbott among steady healthcare picks for long‑term growth (dividend history, nutrition and Libre growth cited), supporting longer‑term investor interest even if near‑term volatility persists. Best Healthcare Stocks to Buy Right Now for Long-Term Growth
• Negative Sentiment: Analyst actions and comments are mixed: BTIG cut its price target (though maintained a Buy), signaling revised near‑term expectations; downward PT moves can pressure the stock. BTIG lowers price target on Abbott
• Negative Sentiment: Market concern about a recent soft quarter and a revenue miss (and the stock’s slide from its 52‑week high) is keeping selling pressure; near‑term headwinds include currency and macro uncertainty. This Dividend King Is Down 26%. When Will It Bounce Back?
• Negative Sentiment: Short‑term price action: coverage noting recent daily dips and lower trading volume versus average suggests current momentum is weak despite the strategic positives. Abbott (ABT) Dips More Than Broader Market: What You Should Know

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.